Nexthera Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Nexthera Capital’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,583,954	Closed	-$5.83M	–	53
2018 Q3	$5.83M	Buy	+1,583,954	New	+$4.72M	1.12%	23

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Nexthera Capital's ACHN Position: Q4 2018 in Review

Nexthera Capital sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 1,583,954 shares — an estimated $5.83M sold.

Nexthera Capital first reported a position in ACHN in Q3 2018 and held it in 1 quarter. The position peaked at $5.83M in Q3 2018. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

Nexthera Capital reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 1,583,954 Achillion Pharmaceuticals shares in Q4 2018, an estimated $5.83M.
Nexthera Capital first reported a position in Achillion Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Nexthera Capital's Achillion Pharmaceuticals position peaked at $5.83M in Q3 2018.
121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.